India’s pharmaceutical dominance is no longer up for debate; it honestly never was. It is the world’s biggest provider of generic drugs, known especially for the affordable vaccines and high-quality medicines it can produce.
In fact, the Indian pharmaceutical industry is currently ranked 3rd in terms of pharmaceutical production by volume. With an impressive CAGR of 9.5% in the last decade, the industry contributes around 1.72% to India’s GDP.
The Global Generics Powerhouse: India’s GDP Edge
Add to this the advent of new age drugs and lifestyle supplements that has the world running to pharmacies. Be it the latest global craze that is GLP for weight loss or the sudden demand for protein substitutes and vitamins. The post-COVID world is different from what it used to be.
And in such times, 2 of India’s microcap pharma companies that not many know about are logging in enviable capital efficiency and sustained growth. Let us look at these two stocks.
Wanbury Ltd: A Case Study in Capital Efficiency
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research.
With a market cap of Rs 741 cr, the company is majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence.
The company has a current ROCE (Return on Capital Employed) of 37%, which is almost 2.5 times the current industry median of 15%. In simple words, Wanbury generates a profit of Rs 37 on every Rs 100 it uses as capital for business, while its peers average about Rs 15.
The 5-year average ROCE of the company is also an impressive 38%, while the industry median for the same period is 17%. Which means the company has managed to hold a sustained grip on capital efficiency.
The promoter holdings of the company have climbed by almost 3.5% between the quarters ending June 2025 and December 2025, which possibly highlights that the promoters are getting more of their skin into the game.
Let us look at the core financials of the company (standalone) to check if it has what it takes to sustain the capital efficiency.
The sales of the company grew from Rs 367 cr to Rs 600 cr between FY20 and FY25, which is a compound growth of 10%. And for H1FY26, the sales recorded by the company were Rs 323 cr. The Figures for the quarter ending December 2025 are awaited.
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) went from Rs 23 cr in FY20 to Rs 77 cr in FY25, which is a compound growth of 27%. And for H1FY26, the EBITDA logged is Rs 50 cr already.
The net profits took a hit after FY20, but by the looks of it are on what could be called a bounce back.
| Year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
| Profits/Rs Cr | 64 | -13 | 81 | -10 | 30 | 31 |
For H1FY26, the company has recorded net profits of Rs 28 cr already, which hints towards a stronger finish for FY26.
The share price of Wanbury Ltd was around Rs 60 in January 2021 and as of closing on 29th January 2026 it was Rs 209, which is a jump of 255% in 5 years. Rs 1 lakh invested in the company 5 years ago would have been over Rs 3.50 lakhs today.
Wanbury Ltd Share Price Chart
At the current price of Rs 209, the stock is trading at a discount of 37% from its all-time high of Rs 330.
The stock is trading at a PE of a 17x which is less than the current industry median of 29x. The 10-Year median PE for Wanbury is 25x and the industry median for the same period is 29x.
In the company’s last investor presentation from November 2025, Mohan Kumar Rayana, Promoter & Whole Time Director said, “With our CAPEX plan on its way for introduction of new products, we remain committed to sustainable growth, increasing capacities, sustaining operational efficiencies and maintaining the highest standards of quality and compliance. Our efforts are aimed at strengthening Wanbury’s position as a trusted global pharmaceutical partner while driving long-term value for all stakeholders.”
Infinium Pharmachem: The SME High-Growth Play
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodine based Pharmaceutical Intermediates.
With a market cap of Rs 337 cr the company’s manufacturing capabilities and technical expertise have catered to industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics, etc.
Apart from these, it provides a range of Iodine derivatives in the market, with more than 200 intermediates and over 7 APIs.
SME Investing: Rewards vs. Risks
Now before we dive into the stock further, please note that the stock is listed EMERGE – NSE’s SME Exchange. And as always, SME stocks come with a warning: buyer beware. The requirement to trade in fixed lots creates a liquidity bottleneck, often leaving investors stranded when prices crash.
Additionally, the tiny equity base of these companies invites manipulation, fuelling ‘pump and dump’ schemes designed to trap retail capital. And lenient reporting standards frequently mask poor financial health, which the investors only come to know about when it’s too late.
However, what makes us add this stock here is the interest of the market’s big whale in it. Ashish Kacholia holds a 4.6% stake in the company worth almost Rs 16 cr, as per screener. The backing of a super investor like Kacholia builds trust in investors to some extent for a SME stock.
The company has a 5-year average ROCE of 30%, which is much higher than the industry median for the same period, which is 17%. Add to this the company’s debt free status, giving them the freedom to use the profits to grow the business, without having to worry about huge interest payments.
Let us now look at the financials of the company.
The sales of the company jumped from Rs 39 cr in FY20 to Rs 156 in FY25, recording a compound growth of 32%. For H1FY26, the sales recorded by the company were Rs 84 cr.
The EBITDA jumped from Rs 2 cr in FY20 to Rs 19 cr in FY25, which is a compound growth of 57%. And for H1FY26, the EBITDA logged is Rs 10 cr.
The net profits saw a roller coaster ride between FY20 and FY25
| Year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
| Profits/Rs Cr | 1 | 3 | 7 | 10 | 12 | 8 |
However, for H1FY26, the company has logged profits of Rs 7 cr already, hinting at a much stronger finish for FY26.
The share price of Infinium Pharmachem Ltd was around Rs 90 when listed in April 2023 and as of closing on 29th January 2026 it was Rs 216, which is a 140% jump.
Infinium Pharma Share Price Chart
At the current price of Rs 216, the stock is trading at a discount of 45% from its all-time high of Rs 392.
The company’s stock is trading at a PE of 36x, and the current industry median is 29x. While it would be too soon to look at a long-term PE median for the company, the 10-year median for the industry is 29x.
According to the November 2025 investor presentation, the company aims to achieve a total revenue target of Rs 200 cr by the end of FY26, driven by a consistent 20% year-over-year growth rate. This expansion includes a sustainable profit margin of 10% over the next two years and a blended EBITDA target of 22% once the Contrast Media segment becomes operational.
For the Contrast Media division specifically, management anticipates initial sales of Rs 30 cr in FY26, scaling rapidly to Rs 80–100 cr by FY27, with a long-term goal of reaching Rs 300 cr in revenue and a 30% EBITDA margin within five years.
To support this trajectory, the company is targeting a 14% market share and currently maintains 16 approved products under EU-REACH registration, with one additional product in development.
The Right Drug: Efficiency, the Ultimate Valuation Lever
While India’s pharmaceutical heavyweights dominate headlines, these microcap outliers demonstrate that capital efficiency, not just sheer size, is the true engine of shareholder value. Wanbury’s massive ROCE outperformance and Infinium’s aggressive expansion into the contrast media segment highlight a shift toward specialized, high-margin manufacturing.
However, for retail investors, the SME exchange’s liquidity constraints remain a critical hurdle. Success in this niche requires a balanced approach. Despite being backed by one of the most followed super investors of India, maintaining a strict margin of safety against microcap volatility is not to be ignored.
Having said that, it would be a fascinating ride to watch how these two stocks fare in the near and long-term future. Add them to a watchlist and watch them closely if you do not want to miss out on any big opportunity.
Disclaimer:
Note: We have relied on data from www.Screener.in and www.trendlyne.com throughout this article. Only in cases where the data was not available, have we used an alternate, but widely used and accepted source of information.
The purpose of this article is only to share interesting charts, data points and thought-provoking opinions. It is NOT a recommendation. If you wish to consider an investment, you are strongly advised to consult your advisor. This article is strictly for educative purposes only.
Suhel Khan has been a passionate follower of the markets for over a decade. During this period, He was an integral part of a leading Equity Research organisation based in Mumbai as the Head of Sales & Marketing. Presently, he is spending most of his time dissecting the investments and strategies of the Super Investors of India.
Disclosure: The writer and his dependents do not hold the stocks discussed in this article.
The website managers, its employee(s), and contributors/writers/authors of articles have or may have an outstanding buy or sell position or holding in the securities, options on securities or other related investments of issuers and/or companies discussed therein. The content of the articles and the interpretation of data are solely the personal views of the contributors/ writers/authors. Investors must make their own investment decisions based on their specific objectives, resources and only after consulting such independent advisors as may be necessary.